QC
FBRX icon

Quadrature Capital’s Forte Biosciences FBRX Stock Holding History

Quadrature Capital’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$482K Buy
18,622
+1,049
+6% +$30.2K 0.01% 801
2025
Q4 		$479K Buy
+17,573
New +$308K ﹤0.01% 705

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Quadrature Capital's FBRX Position: Q1 2026 in Review

Quadrature Capital increased its Forte Biosciences (FBRX) stake by 6% in Q1 2026, buying an estimated $30.2K and bringing the position to 18,622 shares worth $482K. The position accounts for 0.01% of the portfolio, ranked #801.

Quadrature Capital first reported a position in FBRX in Q4 2025 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Quadrature Capital held 18,622 shares of Forte Biosciences worth $482K as of Q1 2026.
  • Quadrature Capital bought 1,049 Forte Biosciences shares in Q1 2026, an estimated $30.2K.
  • Forte Biosciences made up 0.01% of Quadrature Capital's portfolio in Q1 2026, its #801 holding.
  • Quadrature Capital first reported a position in Forte Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.